Sramana Mitra: Yes. On the process side, we’ve had a company become quite successful in the program. It is bootstrapped. We looked at raising money, but eventually, it was going fine as a bootstrapped company. I think it continues to bootstrap. It’s called CliniOps.
>>>These days, everyone seems to be a startup mentor.
Whether they have ever done a startup or not, whether they have ever raised money or not, they are ready to advise entrepreneurs.
I want to share some things we have learned in running the 1Mby1M program since 2010.
First, it is difficult to give negative feedback to entrepreneurs without triggering a defensive reaction. But it is necessary.
Today’s 668th FREE online 1Mby1M Roundtable for Entrepreneurs is starting NOW, on Thursday, January 16, at 8 a.m. PST / 11 a.m. EST / 5 p.m. CET / 9:30 p.m. India IST. CLICK HERE to join. PASSWORD: startup All are welcome!
Today’s 668th FREE online 1Mby1M Roundtable for Entrepreneurs is starting in 30 minutes, on Thursday, January 16, at 8 a.m. PST / 11 a.m. EST / 5 p.m. CET / 9:30 p.m. India IST. CLICK HERE to join. PASSWORD: startup All are welcome!
Sramana Mitra: Now, let’s shift to medical imaging, which is another area where AI is having lots of impact. There are lots of companies working in this field, and lots of entrepreneurial efforts going on in this field. The question that I’m of thinking about is that, are these going to be unicorn style opportunities?
>>>Sramana Mitra: Google’s AlphaFold is a good example of a model. A lot of scientists have been given access to it at an affordable price point. The impact it is having on scientific discovery and research is humongous. Somewhere in this continuum, I see that there’s a missing area where there is no Platform as a Service (PaaS) like AlphaFold that scientists can tap into to do drug discovery work using AI.
>>>Are you thinking of starting a venture alone in 2025?
Fred Luddy founded ServiceNow as a Solo Entrepreneur Bootstrapping with a Paycheck.
Today, ServiceNow is one of history’s most successful SaaS companies.
The Small Molecule Drug Discovery Market is estimated to grow at 9% CAGR from $74.08 billion in 2024 to reach $175.41 billion by 2034. San Francisco-based Atomwise is one player that is making use of its AI capabilities to make a mark in the industry.
>>>